Faratian D, Bartlett J (2007) Predictive markers in breast cancer-the future. Histopathology 52(1):91–98

Article  Google Scholar 

Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G (2020) HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol 38(17):1951–1962

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. J Clin Oncol 36(20):2105–2122

Article  CAS  PubMed  Google Scholar 

Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P (2014) A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 american society of clinical oncology/ college of american pathologists criteria. Arch Pathol Lab Med 138(2):213–219

Article  PubMed  Google Scholar 

Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau J-F, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N (2020) NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J Clin Oncol 38(5):444–453

Article  CAS  PubMed  Google Scholar 

Ali A, Graff SL (2024) Exploring DESTINY: the past, present, and future of trastuzumab deruxtecan. Curr Oncol Rep 26(1):1–9

Article  CAS  PubMed  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, Italiano A, Kao S, Piha-Paul SA, Delord J-P, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Fan J, Norwood K, Yung-Jue B (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365

Article  CAS  PubMed  Google Scholar 

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, De Miranda NFDCC, Trajanoski Z (2019) Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med 11(1):20

Google Scholar 

Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang NJ (2015) Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer 13(1):e37–e49

Article  PubMed  Google Scholar 

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J (2018) Microsatellite instability status determined by next-generation sequencing and compared with <scp>PD</scp>-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7(3):746–756

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitri ZI, Abuhadra N, Goodyear SM, Hobbs EA, Kaempf A, Thompson AM, Moulder SL (2022) Impact of TP53 mutations in triple negative breast cancer. npj Precis Oncol. https://doi.org/10.1038/s41698-022-00303-6

Article  PubMed  PubMed Central  Google Scholar 

Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-020-00208-

Article  PubMed  PubMed Central  Google Scholar 

Pascual J, Turner NC (2019) Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol 30(7):1051–1060

Article  CAS  PubMed  Google Scholar 

Martín M, Chan A, Dirix L, O’Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S (2017) A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol 28(2):313–320

Article  PubMed  Google Scholar 

Mukohara, T. (2015). PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer: Targets and Therapy. 111.

Criscitiello C, Viale G, Curigliano G, Goldhirsch A (2018) Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. Breast Cancer: Targ and Ther 10:23–29

CAS  Google Scholar 

Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2(10):1354–1360

Article  PubMed  Google Scholar 

Paijens ST, Vledder A, de Bruyn M, Nijman HW (2021) Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 18(4):842–859

Article  CAS  PubMed  Google Scholar 

Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22(5):725–733

Article  CAS  PubMed  Google Scholar